Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMID 14678862)

Published in Am J Med on December 08, 2003

Authors

John D Brunzell1, Amir F Ayyobi

Author Affiliations

1: Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, Washington 98195-6178, USA.

Articles citing this

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49

The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr (2009) 1.25

Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches. Exp Clin Cardiol (2007) 1.15

Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14

Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes (2012) 1.08

Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci (2013) 0.94

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome. Cardiovasc Diabetol (2011) 0.91

Overexpression of apolipoprotein A5 in mice is not protective against body weight gain and aberrant glucose homeostasis. Metabolism (2009) 0.88

Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. Cardiovasc Diabetol (2013) 0.84

Greenselect phytosome for borderline metabolic syndrome. Evid Based Complement Alternat Med (2013) 0.81

Geraniol, alone and in combination with pioglitazone, ameliorates fructose-induced metabolic syndrome in rats via the modulation of both inflammatory and oxidative stress status. PLoS One (2015) 0.80

Reduced apolipoprotein glycosylation in patients with the metabolic syndrome. PLoS One (2014) 0.78

Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health (2015) 0.77

Obese first-degree relatives of patients with type 2 diabetes with elevated triglyceride levels exhibit increased β-cell function. Metab Syndr Relat Disord (2014) 0.75

Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes. Exp Ther Med (2014) 0.75

Plasma Proteomic Signature in Overweight Girls Closely Correlates with Homeostasis Model Assessment (HOMA), an Objective Measure of Insulin Resistance. Hum Genomics Proteomics (2011) 0.75

The role of Spectral Domain Optical Coherence Tomography in monitoring uncontrolled hypertensive type 2 diabetic patients. J Med Life (2014) 0.75

Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. Drugs Aging (2012) 0.75

Sex differences in HDL ApoC-III in American Indian youth. Biol Sex Differ (2012) 0.75

Leptin Receptor Gene Gln223Arg Polymorphism Is Not Associated with Hypertension: A Preliminary Population-Based Cross-Sectional Study. Cardiol Res Pract (2014) 0.75